The coexistence of field-induced slow magnetic relaxation and moderately large magnetocaloric efficiency in the supra-Kelvin temperature region occurs in the 2D compound [Gd^III ₂(ox)₃(H₂O)₆]_n·4nH₂O (1), a feature that can be exploited in the proof-of-concept design of a new class of slow-relaxing magnetic materials for cryogenic magnetic refrigeration.

Two one-dimensional dysprosium(III) complexes based on α-glycine (gly) and β-alanine (β-ala) amino acids, with the formula {[Dy₂(gly)₆(H₂O)₄](ClO₄)₆·5H₂O}_n (1) and {[Dy₂(β-ala)₆(H₂O)₄](ClO₄)₆·H₂O}_n (2), have been synthesised and characterised structurally and magnetically. Both compounds crystallise in the triclinic system with the space group P. In 1, two Dy^III ions are eight-coordinate and bound to six oxygen atoms from six gly ligands and two oxygen atoms from two water molecules, showing different geometries (bicapped trigonal prism and square antiprism). In 2, two Dy^III ions are nine-coordinate and bound to seven oxygen atoms from six β-ala ligands and two oxygen atoms from two water molecules in the same geometry (capped square antiprism). In the crystal packing of both compounds, cationic {[Dy₂(L)₆(H₂O)₄]⁶⁺}_n [L = α-glycine (1) and β-alanine (2)] chains, ClO₄ ⁻ anions, and water molecules generate a network connected through H-bonding interactions. The study of the magnetic properties of 1 and 2 through dc magnetic susceptibility measurements reveals different magnetic behaviour 1 and 2. In addition, ac magnetic susceptibility measurements show a field-induced slow relaxation of magnetisation for both compounds, pointing out that the single-molecule magnet (SMM) phenomenon occurs in both 1 and 2.

Gadolinium (III) complexes exhibiting slow relaxation of magnetization are uncommon and have been much less studied than other compounds based on anisotropic lanthanide (III) ions. We prepared two one-dimensional gadolinium (III) complexes based on α-glycine (gly) and β-alanine (β-ala) amino acids, with the formula {[Gd₂(gly)₆(H₂O)₄](ClO₄)₆·5H₂O}_n (1) and {[Gd₂(β-ala)₆(H₂O)₄](ClO₄)₆·H₂O}_n (2), which were magneto-structurally characterized. Compounds 1 and 2 crystallize in the triclinic system (space group Pī). In complex 1, two Gd (III) ions are eight-coordinate and bound to six oxygen atoms from six gly ligands and two oxygen atoms from two water molecules, the metal ions showing different geometries (bicapped trigonal prism and square antiprism). In complex 2, two Gd (III) ions are nine-coordinate and bound to seven oxygen atoms from six β-ala ligands and two oxygen atoms from two water molecules in the same geometry (capped square antiprism). Variable-temperature dc magnetic susceptibility measurements performed on microcrystalline samples of 1 and 2 show similar magnetic behavior for both compounds, with antiferromagnetic coupling between the Gd (III) ions connected through carboxylate groups. Ac magnetic susceptibility measurements reveal slow relaxation of magnetization in the presence of an external dc field in both compounds, hence indicating the occurrence of the field-induced single-molecule magnet (SMM) phenomenon in both 1 and 2.

The paramagnetic gadolinium(III) ion is used as contrast agent in magnetic resonance (MR) imaging to improve the lesion detection and characterization. It generates a signal by changing the relaxivity of protons from associated water molecules and creates a clearer physical distinction between the molecule and the surrounding tissues. New gadolinium-based contrast agents displaying larger relaxivity values and specifically targeted might provide higher resolution and better functional images. We have synthesized the gadolinium(III) complex of formula [Gd(thy)₂(H₂O)₆](ClO₄)₃·2H₂O (1) [thy = 5-methyl-1H-pyrimidine-2,4-dione or thymine], which is the first reported compound based on gadolinium and thymine nucleobase. 1 has been characterized through UV-vis, IR, SEM-EDAX, and single-crystal X-ray diffraction techniques, and its magnetic and relaxometric properties have been investigated by means of SQUID magnetometer and MR imaging phantom studies, respectively. On the basis of its high relaxivity values, this gadolinium(III) complex can be considered a suitable candidate for contrast-enhanced magnetic resonance imaging.

Metal complexes based on purine nucleobases can be a very useful tool in the diagnosis and treatment of some diseases as well as in other biomedical applications. We have prepared and characterized a novel dinuclear ruthenium(III) complex based on the nucleobase adenine of formula [{Ru(μ-Cl)(μ-Hade)}₂Cl₄]Cl₂·2H₂O (1) [Hade = protonated adenine]. Complex 1 was characterized through Fourier transform infrared spectroscopy (FT-IR), scanning electron microscopy and energy dispersive X-ray analysis (SEM-EDX), magnetometer (SQUID) and cyclic voltammetry (CV) techniques. The crystal structure of 1 was determined by single-crystal X-ray diffraction. 1 crystallizes in the monoclinic system with space group P2₁/n. Each ruthenium(III) ion is six-coordinate and bonded to four Cl atoms [the average value of the Ru^III-Cl bonds lengths is ca. 2.329(1) Å] and two N atoms (N3 and N9) from two adenine molecules, the N1 atom being protonated in both of them. The anticancer activity was evaluated through cell viability assays performed on a colon cancer (HCT116) and a gastric cancer cell lines (AGS), 1 showing an incipient anticancer effect on the AGS cell line at the highest concentration used in the study.